 Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. In addition, Oyster Point Pharma intends to grant the underwriters a 30-day option to purchase up to 375,000 additional shares of common stock at the public offering price less underwriting discounts and commissions. J.P. Morgan Securities LLC, Cowen and Company, LLC and Piper Sandler Co. are acting as joint book-running managers for the offering. 